Halozyme Therapeutics Inc
NASDAQ:HALO
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.68
64.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Halozyme Therapeutics Inc
Wall Street
Price Targets
HALO Price Targets Summary
Halozyme Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
HALO
is 63.69 USD
with a low forecast of 50.5 USD and a high forecast of 78.75 USD.
HALO Last Price Targets
Halozyme Therapeutics Inc
The latest public price target was made on Nov 15, 2024 by
Joseph Catanzaro
from
Piper Sandler
,
who expects
HALO
stock to
rise by 6%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Joseph Catanzaro
Piper Sandler
|
52
USD
Upside 6% |
1 week ago
Nov 15, 2024
|
Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)
StreetInsider
|
Mohit Bansal
Wells Fargo
|
58
USD
Upside 18% |
5 months ago
Jun 7, 2024
|
Halozyme Therapeutics (HALO) PT Raised to $58 at Wells Fargo
StreetInsider
|
|
Joseph Catanzaro
Piper Sandler
|
51
USD
Upside 4% |
5 months ago
Jun 7, 2024
|
Halozyme downgraded to Neutral after rally at Piper Sandler
TheFly
|
|
Mitchell Kapoor
H.C. Wainwright
|
65
USD
Upside 32% |
5 months ago
Jun 7, 2024
|
Halozyme Therapeutics (HALO) PT Raised to $65 at H.C. Wainwright
StreetInsider
|
Corinne Jenkins
Goldman Sachs
|
44
USD
Downside 10% |
5 months ago
Jun 6, 2024
|
Halozyme price target raised to $44 from $41 at Goldman Sachs
TheFly
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is HALO's stock price target?
Price Target
63.69
USD
According to Wall Street analysts, the average 1-year price target for
HALO
is 63.69 USD
with a low forecast of 50.5 USD and a high forecast of 78.75 USD.
What is Halozyme Therapeutics Inc's Revenue forecast?
Projected CAGR
20%
For the last 8 years the
compound annual growth rate for
Halozyme Therapeutics Inc's revenue is
25%.
The projected
CAGR
for the next 3 years is
20%.
What is Halozyme Therapeutics Inc's Operating Income forecast?
Projected CAGR
38%
The
compound annual growth rate
of Halozyme Therapeutics Inc's operating income for the next 3 years is
38%.
What is Halozyme Therapeutics Inc's Net Income forecast?
Projected CAGR
42%
The
compound annual growth rate
of Halozyme Therapeutics Inc's net income for the next 3 years is
42%.
You don't have any saved screeners yet
